Fulcrum Therapeutics
FULC
116 hedge funds and large institutions have $172M invested in Fulcrum Therapeutics in 2023 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 50 increasing their positions, 22 reducing their positions, and 21 closing their positions.
1,332% more call options, than puts
Call options by funds: $1.98M | Put options by funds: $138K
127% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 22
33% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 21
6% more funds holding
Funds holding: 109 → 116 (+7)
1.28% more ownership
Funds ownership: 96.54% → 97.82% (+1.3%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
53% less capital invested
Capital invested by funds: $366M → $172M (-$194M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$23.7M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$18.8M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$9.69M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.27M |
| 5 |
BlackRock
New York
|
+$8.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$14.6M |
| 2 |
TGI
TRV GP III
Boston,
Massachusetts
|
-$14.3M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$5.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$5.44M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$4.6M |
FULC Hedge Fund Activity: Q1 2023 in Review
116 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q1 2023, worth a combined $172M — down 53% from $366M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new FULC positions and 21 closed out — a net gain of 7 holders — while 50 added to existing stakes and 22 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $23.7M. The largest seller was Logos Global Management, exiting entirely with an estimated $14.6M sold.
- 116 institutional investors held Fulcrum Therapeutics (FULC) as of Q1 2023, up from 109 in Q4 2022.
- Funds reported $172M of Fulcrum Therapeutics stock for Q1 2023, down 53% quarter-over-quarter.
- 28 funds opened new Fulcrum Therapeutics positions in Q1 2023 and 21 closed out, a net change of +7 holders.
- The largest Fulcrum Therapeutics buyer in Q1 2023 was Point72 Asset Management, an estimated $23.7M added.
- The largest Fulcrum Therapeutics seller in Q1 2023 was Logos Global Management, an estimated $14.6M sold.
Based on aggregated 13F filings for Q1 2023.